Advances in the pathophysiology of primary immune thrombocytopenia
Authors:
- 27 September 2016
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 22 (1) , 41-53
Abstract
Objectives: Classically, immune thrombocytopenia (ITP) was thought to be caused by the destruction and insufficient production of platelets, as mediated by autoantibodies. More recently other immune mechanisms that contribute to the disease have been discovered. This review attempts to address the main unresolved questions in ITP. Methods: We review the most current knowledge of the pathophysiology of ITP. Immunological effects of available therapies are also described. Discussion: The trigger may be a loss of tolerance due to molecular mimicry with cross-reaction of antibodies arising from infectious agents or drugs, genetic factors, and/or platelet Toll receptors. This loss of tolerance activates autoreactive effector B and T lymphocytes, which in turn initiates platelet destruction, mediated by cytotoxic T lymphocytes and the release of pro-inflammatory cytokines (IL-2/IL-17) by T helper (Th) cells (Th1/Th17). Th2 (anti-inflammatory) and regulatory B (Breg) and Treg cells are also inhibited (with decrease in IL-10/TGF-β), which leads to the disease becoming chronic. Some isotypes of autoantibodies may increase the bleeding risk. Corticosteroids, rituximab, and thrombopoietin receptor agonists (A-TPOs) all increase levels of Tregs and TGF-β. The A-TPOs also increase Breg levels, which could explain why complete remission has been seen in some cases. Conclusion: A better understanding of the immunomodulatory effects of each ITP therapy is needed to best manage the disease.Keywords
Funding Information
- Amgen S.A
This publication has 87 references indexed in Scilit:
- Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune ThrombocytopeniaJournal of Immunology Research, 2013
- B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsJournal of Clinical Investigation, 2012
- The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune ThrombocytopeniaPLOS ONE, 2012
- DNA Methyltransferase 3B Gene Promoter and Interleukin-1 Receptor Antagonist Polymorphisms in Childhood Immune ThrombocytopeniaJournal of Immunology Research, 2012
- Immunologic effects of rituximab on the human spleen in immune thrombocytopeniaBlood, 2011
- The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopeniaHaematologica, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine modelJournal of Allergy and Clinical Immunology, 2010
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001